Overview

Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection

Status:
Completed
Trial end date:
2018-04-04
Target enrollment:
0
Participant gender:
All
Summary
This study purposed to examine the adequate range of therapeutic concentration for Korean people by observing curative effects, side effects, blood concentration, etc. in treating CRAB-infected patients with colistin.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
DongGuk University
Treatments:
Colistin
Criteria
Inclusion Criteria:

1. All adult patients (aged ≥18 years)

2. Microbiological evidence (sputum, urine, blood) of infection due to
carbapenem-resistant Acinetobacter baumannii during hospitalization

3. Intravenous Colistimethate sodium treated patient with Acinetobacter baumannii
infection who fulfill the above criteria

4. Patients who agree to the gathering clinical information by means of an informed
consent

Exclusion Criteria:

1. Pregnancy and lactating women

2. Patients receiving Colistimethate sodium therapy for <48 hours

3. Patient of chronic renal disease defined as a Creatinine clearance <10 mL/min, Or
requirement for peritoneal or hemo-dialysis or hemofiltration

4. Known hypersensitivity to Colistimethate sodium

5. Receiving intravenous colistin therapy within the past 30 days

6. Patients treated with nebulized Colistimethate sodium